raloxifene hydrochloride has been researched along with menaquinone 6 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, Y | 1 |
| Ishii, J | 1 |
| Iwamoto, J; Rowley, E; Sato, M; Schmidt, A; Stanfield, L; Takeda, T; Yeh, JK | 1 |
| Hagino, H | 1 |
| Saito, M | 1 |
| Masaki, H; Miki, T | 1 |
| Altunay, H; Bilgili, H; Gecit, MR; Keskin, D; Tasci, AG | 1 |
5 review(s) available for raloxifene hydrochloride and menaquinone 6
| Article | Year |
|---|---|
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; Humans; Isoflavones; Japan; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; United States; Vitamin K 2 | 2002 |
[Combination therapy for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2007 |
[Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Collagen; Diphosphonates; Glycation End Products, Advanced; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2008 |
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Vitamin K 2 | 2008 |
2 other study(ies) available for raloxifene hydrochloride and menaquinone 6
| Article | Year |
|---|---|
Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Topics: Administration, Oral; Animals; Bone Density; Compressive Strength; Disease Models, Animal; Drug Therapy, Combination; Female; Femur Neck; Lumbar Vertebrae; Osteocalcin; Osteogenesis; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2005 |
Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats.
Topics: Animals; Blood Chemical Analysis; Bone Density; Drug Therapy, Combination; Female; Femur; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tibia; Uterus; Vitamin K 2 | 2011 |